Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
52.56%
Operating Margin
9.58%
Net Margin
17.32%
Efficiency Metrics
Revenue per Expense Ratio
1.11
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
57.67%
Income Tax Rate
7.37%
EPS
3.1000000000
Balance Sheet Analysis
Current Ratio
0.70
Cash Ratio
0.34
Working Capital
$-1.43B
Debt to Equity
0.99
Debt to Assets
43.00%
Equity Ratio
43.34%
Cash Flow Analysis
Operating Cash Flow Ratio
29.85%
Free Cash Flow Ratio
-34.52%
CapEx to Revenue
64.37%
Dividends Paid
$1.52B
Stock Buybacks
No buybacks
Total Shareholder Returns
$1.52B
Cash Position Change
985.94%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 0.52%
Detailed Growth Metrics
Core Performance
Revenue
16.74%
Net Income
151.23%
EPS
162.71%
Operating Income
-11.10%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
8.26%
Operating Cash Flow
-1.48%
Free Cash Flow
266.19%
Balance Sheet Health
Assets
6.34%
Debt
4.98%
Book Value per Share
2.61%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
0.52%
Shares Outstanding
4.28%
Long Term Trends
3Y Revenue/Share
22.22%
5Y Revenue/Share
24.05%
3Y Dividend/Share
6.88%
5Y Dividend/Share
12.73%